Business Development

Our business strategy is to do what we do best — develop our ZFP technology through research, preclinical and early stage clinical testing. We then look for partners to help us fully realize the value of certain programs through late stage clinical trials and commercialization.

Partnering

Our plan is to partner certain programs at points of value inflection. In early 2012 we established a partnership with Shire AG to develop ZFP Therapeutics for hemophilia, Huntington's disease and other monogenic diseases.

 

SB728 hemophilia hemoglobinopathies rare_diseases other_indications

For information about:
Existing Partnerships
Research Collaborations

To contact our Business Development team, please email: busdev@sangamo.com